Impact of cytokine gene polymorphism on cardiovascular risk in renal transplant recipients

Transplant International

Volumn 18, Issue 6, 2005, Pages 681-689

  Altun, Bülent ^a   Yilmaz, Rahmi ^a   Kahraman, Serkan ^a   Gençtoy, Gültekin ^a   Arici, Mustafa ^a   Önalan, Orhan ^a   Oto, Aytekin ^a   Hayran, Mutlu ^a   Bakkaloǧlu, Mehmet ^a   Yasavul, Ünal ^a   Turgan, Çetin ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Cardiovascular disease; Cytokine; Transplantation

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; FIBRINOGEN; HOMOCYSTEINE; INTERLEUKIN 10; LIPOPROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; LIPOPROTEIN A; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ALLOGRAFT; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CODON; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FIBRINOGEN BLOOD LEVEL; GENETIC POLYMORPHISM; GENOTYPE; HEART LEFT VENTRICLE MASS; HUMAN; INFLAMMATION; INTIMA; KIDNEY TRANSPLANTATION; LIPOPROTEIN BLOOD LEVEL; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; BLOOD; CARDIOVASCULAR DISEASE; CAROTID ARTERY; GENETICS; HEART LEFT VENTRICLE HYPERTROPHY; MIDDLE AGED; PATHOLOGY;

ADULT; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; CYTOKINES; FEMALE; GENOTYPE; HOMOCYSTEINE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY TRANSPLANTATION; LIPOPROTEIN(A); MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA; TUNICA INTIMA;

EID: 23244464065     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2005.00118.x     Document Type: Article

References (36)

1. Ojo AO, Hanson JA, Wolfe RA. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307.
2. Wendelhag I, Wiklund O, Wikstrand J. Arterial wall thickness in familial hypercholesterolemia: ultrasound measurement of intima media thickness in the common carotid artery. Arteriosder Thromb 1992; 12: 70.
3. Barbagallo CM, Pinto A, Gallo S, et al. Carotid atherosclerosis in renal transplant recipients. Transplantation 1999; 67: 366.
4. McGregor E, Stewart G, Rodger RSC, et al. Early echocardiographic changes and survival following renal transplantation. Nephrol Dial Transplant 2000; 15: 93.
5. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115.
6. Jeron A, Straub RH, Kaiser T, et al. Systemic immunosuppression fails to suppress cardiac cytokine induction in pressure overload hypertrophy in rats, Immunobiology 2002; 205: 51.
7. Wilson A, Symons J, McDowell T, et al. Effects of a polymorphism in the human tumor necrosis factor-α promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94: 3195.
8. Lee SC, Pu YB, Thomas GN, et al. Tumor necrosis alpha gene G-308A polymorphism in the metabolic syndrome. Metabolism 2000; 49: 1021.
9. Allen RA, Lee EM, Roberts DH, et al. Polymorphisms in the TNF-α and TNF gene-receptor genes in patients with coronary artery disease. Eur J Clin Invest 2001; 31: 843.
10. Daftarian PM, Kumar A, Kryworuchko M, et al. IL-10 production is enhanced in human T cells by IL-12 and IL-6 in monocytes by tumor necrosis factor-α. J Immunol 1996; 157: 12.
11. Pinderski Oslund LJ, Hedrick CC, Olvera T, et al. IL-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 1999; 19: 2823.
12. Turner DM, Williams DM, Sankaran D, et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24: 1.
13. George S, Turner D, Reynard M, et al. Significance of cytokine gene polymorphism in renal transplantation. Transplant Proc 2001; 33: 483.
14. Grainger DJ, Heathcote K, Chiano M, et al. Genetic control of the circulating concentration of transforming growth factor type β1. Hum Mol Genet 1999; 8: 93.
15. Cambien F, Ricard S, Troesch A, et al. Polymorphisms of the transforming growth factor-β1 gene in relation to myocardial infarction and blood pressure (ECTIM study). Hypertension 1996; 28: 881.
16. Devereux R, Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 1977; 55: 613.
17. Hoffmann CS, Stanley ME, Cox DE, et al. Ethnicity greatly influences cytokine gene polymorphism distribution. Am J Transplant 2002; 2: 560.
18. Mizia-Stec K, Mandecki T, Zahorska-Markiewicz B, et al. Is there a relationship between left ventricular systolic function and serum cytokines level in patients with coronary artery disease? Med Sci Monit 2002; 8: 87.
19. Ridker PM, Rifai N, Pfeffer M, et al. Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149.
20. Bernard V, Pillois X, Dubus I, et al. The -308 G/A tumor necrosis-α gene dimorphism: a risk factor for unstable angina. Clin Chem Lab Med 2003; 41: 511.
21. Keso T, Perola M, Laippala P, et al. Polymorphims within the tumor necrosis factor locus and prevalance of coronary artery disease in middle-aged men. Atherosclerosis 2001; 154: 691.
22. Kubota T, Mc Namara DM, Wang JJ, et al. Effects of tumor necrosis factor gene polymorphisms on patients with congestive heart failure. Circulation 1998; 97: 2499.
23. Densem CG, Hutchinson IV, Yonan N, et al. Influence of tumor necrosis-α Gene -308 polymorphism on the development of coronary vasculopathy after cardiac transplantation. J Heart Lung Transplant 2001; 20: 1265.
24. Smith DA, Irving SD, Sheldon J, et al. Serum levels of the antiinflammatory cytokine inteleukin-10 are decreased in patients with unstable angina. Circulation 2001; 104: 746.
25. Koch W, Kastrati A, Bottiger C, et al. Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. Atherosclerosis 2001; 159: 137.
26. Donger C, Georges JL, Nicaud V, et al. New polymorphisms in the interleukin-10 gene relationships to myocardial infarction. Eur J Clin Invest 2001; 31: 9.
27. Girndt M, Kaul H, Sester U, et al. Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int 2002; 62: 949.
28. Grainger DJ, Mosedale DE, Metcalfe JC, et al. Active and acid activable TGF-β in human sera, platelets and plasma. Clin Chim Acta 1995; 235: 11.
29. Tashiro H, Shimokawa H, Yamamoto K, et al. Altered plasma levels of cytokines in patients with ischemie heart disease. Coron Artery Dis 1997; 8: 143.
30. Grainger DJ, Kemp PR, Metcalfe JC, et al. The serum concentration of active transforming growth factor β is severely depressed in advanced atherosclerosis. Nat Med 1995; 1: 74.
31. Stefoni S, Cianciolo G, Donati G, et al. Low TGF-β1 serum levels are a risk factor for atherosclerosis disease in ESRD patients. Kidney Int 2002; 61: 324.
32. Yokota M, Ichihara A, Lin T-L, et al. Association of a T29 → C polymorphism of the transforming growth factor β1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 2000; 101: 2783.
33. Awad MR, El-Gamel A, Hasleton P, et al. Genotypic variation in the transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998; 66: 1014.
34. Ochsner S, Guo Z, Binswanger U, et al. TGF-β1 gene expression in stable renal transplant recipients: influence of TGF-β1 gene polymorphism and immunosuppression. Transplant Proc 2002; 34: 2901.
35. Syrris P, Carter ND, Metcalfe JC, et al. Transforming growth factor-beta1 gene polymorphisms and coronary artery disease. Clin Sci 1998; 95: 659.
36. Kojima S, Harpel PC, Rifkin DB, et al. Lipoprotein (a) inhibits the generation of transforming growth factor-β: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol 1991; 113: 1439.